← All trials
NCT06002490
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2023
- Primary completion
- Jul 31, 2024
- Completion date
- Jul 31, 2024
- First posted
- Aug 21, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PharmaEssentia Corp.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.